Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
News|Articles|August 6, 2024
Clearside Biomedical sets sights on suprachoroidal drug delivery
Author(s)David Hutton
The company hosted a virtual KOL event focusing on applicability and real-world experience with suprachoroidal drug delivery, the SCS as a differentiator in the retinal treatment landscape with a focus on wet AMD, and ongoing SCS clinical programs.
Advertisement
Advertisement
Clearside Biomedical, Inc recently hosted a virtual key opinion leader (KOL) event focusing on applicability and real-world experience with suprachoroidal drug delivery, the suprachoroidal space (SCS) as a differentiator in the retinal treatment landscape with a focus on neovascular age-related macular degeneration (wet AMD), and ongoing SCS clinical programs, including potential future development opportunities for the company.
Related to this article
Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.
The trial over-enrolled and finished approximately 4 months ahead of initial projections, with 52-week topline data now expected in the second half of 2027.
Ultra-widefield imaging reveals early retinal risk in pediatric patients.
Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.
The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.
Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.
The resubmission is considered a Class 1 submission and has a current PDUFA target action date of July 29, 2026.
Advertisement
Advertisement